pazopanib drug pathway 2012-10-19T16:13:35Z PW:0001132 The pharmacokinetics and pharmacodynamics pathway of pazopanib, a receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma as well as other tumors. Angiogenic factors such as vascular endothelial or platelet derived growth factors are direct and indirect targets of hypoxia inducible factor pathway, constitutively active in renal cell carcinoma. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug. pathway vpetri antineoplastic drug pathway